Yes, hepatitis can remain dormant in your body for years or even decades without causing noticeable symptoms. This is especially true for hepatitis B and hepatitis C, which can both transition into chronic infections that silently damage the liver over 10 to 30 years before anything feels wrong. Hepatitis A, by contrast, never becomes chronic and clears on its own.
Which Types of Hepatitis Can Stay Dormant
Not all hepatitis viruses behave the same way. Hepatitis A causes a short-term illness and does not progress to chronic infection. Once your body clears it, it’s gone. Hepatitis B and C are the ones capable of lingering silently for years, and they do so through very different mechanisms.
Hepatitis B can be a short-term illness for some people, but for others it becomes a lifelong chronic infection. The younger you are when you’re infected, the higher the chance it becomes chronic. Babies infected at birth have roughly a 90% chance of developing chronic hepatitis B, while healthy adults clear the virus about 95% of the time. Hepatitis C is even more likely to persist: somewhere between 50% and 85% of people who contract it become chronic carriers, and most of them have no idea.
How Hepatitis Hides in the Body
Hepatitis B is remarkably good at evading your immune system. Once the virus infects liver cells, it parks a special form of its genetic material inside the cell nucleus. This circular strand of DNA is extremely stable and essentially becomes a permanent resident, quietly producing new copies of the virus. Even when antiviral treatment suppresses the virus to undetectable levels in the blood, this hidden DNA template survives inside liver cells. That’s why stopping treatment often leads to the virus bouncing back.
The virus also actively interferes with your body’s defenses. It produces proteins that suppress the immune cells responsible for detecting and destroying infected cells. One viral protein blocks key signaling pathways that would normally trigger an immune alarm. Another manipulates specialized immune cells in the liver, pushing them toward an anti-inflammatory state that tolerates the virus rather than fighting it. These long-lived immune-suppressing effects help explain why hepatitis B can persist in some patients for decades after infection.
Hepatitis C uses a different strategy but achieves the same result. It replicates steadily at low levels while the immune system mounts an insufficient response. The chronic carrier state is normally asymptomatic but may cause vague, nonspecific feelings of being unwell that are easy to dismiss or attribute to other causes.
How Long the Silent Phase Lasts
The asymptomatic period for chronic hepatitis can stretch across most of a person’s adult life. Up to 30% of chronic hepatitis C carriers will progress to severe liver disease after 14 to 30 years of infection, with an increased risk of liver cancer (roughly 14% of all chronic carriers, and up to 33% of those who develop cirrhosis). The remaining 70% may carry the virus for decades with minimal liver damage, though “minimal” doesn’t mean zero. Slow, cumulative scarring can build up without producing symptoms until the liver is significantly compromised.
Chronic hepatitis B follows a similar timeline. Many carriers go through an “inactive” phase that can last years or even a lifetime, where the virus is present but reproducing at very low levels. During this phase, liver inflammation is minimal and blood tests may look nearly normal. But the virus hasn’t left. It’s still embedded in liver cells, capable of flaring up under the right conditions.
What Can Wake a Dormant Infection
One of the most serious risks of a dormant hepatitis B infection is reactivation, where the virus suddenly ramps up reproduction and causes a new wave of liver inflammation. This happens most often when something suppresses the immune system, removing the very thing that was keeping the virus in check.
Cancer chemotherapy is a major trigger. Certain drugs used for blood cancers carry a reactivation risk of 30% to 60% in people who test positive for the hepatitis B surface antigen. Chemotherapy drugs used for solid tumors, particularly a class called anthracycline derivatives, carry a 15% to 30% risk. High-dose corticosteroids (the equivalent of 20 mg or more of prednisone daily for four weeks or longer) also pose a high risk, above 10%.
Medications for autoimmune and inflammatory conditions are another concern. Drugs used for rheumatoid arthritis, inflammatory bowel disease, psoriasis, and ankylosing spondylitis have all been linked to hepatitis B reactivation. Biological therapies that target specific immune pathways, such as TNF blockers, carry a moderate reactivation risk of 1% to 10%. Even organ transplantation, which requires lifelong immune suppression, can trigger dormant hepatitis B.
Importantly, reactivation can occur even in people whose blood tests show no detectable virus. As long as that stable viral DNA remains inside liver cells, the potential for reactivation exists. This is why doctors should screen for hepatitis B before starting any immunosuppressive therapy.
You Can Spread It Without Knowing
A dormant or asymptomatic hepatitis infection is still a transmissible one. Asymptomatic carriers unknowingly contribute to the transmission chain, representing a hidden reservoir that undermines public health efforts to control these viruses. Hepatitis B spreads through blood, sexual contact, and from mother to child during birth. Hepatitis C spreads primarily through blood-to-blood contact, including shared needles.
Because carriers feel perfectly healthy, they have no reason to suspect they’re infectious. Globally, an estimated 50 million people have chronic hepatitis C, and as of 2022, only about 36% of them knew their diagnosis. That means roughly 32 million people worldwide are carrying hepatitis C without being aware of it.
How Dormant Hepatitis Is Detected
Since dormant hepatitis produces no symptoms, the only way to find it is through blood testing. For hepatitis B, doctors look at a combination of markers. A positive surface antigen (HBsAg) means the virus is currently present, whether acute or chronic. To distinguish between the two, labs check for a specific antibody called IgM anti-HBc, which appears during acute infection but fades in chronic cases. A chronic carrier typically shows a positive surface antigen and a positive total core antibody, but a negative IgM antibody. This pattern can persist for years or even a lifetime.
For hepatitis C, the initial screening test checks for antibodies, which tell you if you’ve ever been exposed. A positive antibody test is followed by a test that looks for the virus’s genetic material in your blood to confirm an active, ongoing infection.
The CDC recommends that all adults aged 18 and older be screened for hepatitis C at least once in their lifetime. All pregnant women should be tested during each pregnancy. People with ongoing risk factors, such as current injection drug use or long-term hemodialysis, should be tested periodically. Anyone who received a blood transfusion or organ transplant before July 1992, or who received clotting factor concentrates before 1987, should also be tested. And any person who simply wants a test should receive one, regardless of whether they disclose specific risk factors.
Why Early Detection Changes the Outcome
The reason screening matters so much is that both hepatitis B and C are now treatable, and catching them during the dormant phase, before significant liver damage has accumulated, produces far better outcomes. Modern antiviral treatments for hepatitis C cure more than 95% of infections in 8 to 12 weeks. Hepatitis B can be managed with long-term antiviral therapy that suppresses the virus and prevents progression to cirrhosis and liver cancer, even though the treatment rarely eliminates the virus completely due to that persistent DNA hiding in liver cells.
Left undetected, the math is less favorable. Up to 30% of untreated chronic hepatitis C carriers develop severe liver disease within two to three decades. Liver cancer risk climbs significantly once cirrhosis is established. These are outcomes that a simple blood test, taken years before symptoms appear, can help prevent.